This study is for patients with a type of lung cancer called non-small cell lung cancer (NSCLC) that has a specific change, or mutation, in a gene called EGFR. The study tests two treatments: osimertinib, a drug that can stop cancer cells from growing, and bevacizumab, which can stop tumors from growing and spreading. Some patients will take only osimertinib, and others will take both drugs to see which works better.

To join, patients must have stage IIIB-IV NSCLC with the EGFR mutation and be over 18 years old. They can't have had certain previous treatments or conditions like heart disease or pregnancy. The study involves taking osimertinib pills daily and, for some, bevacizumab through an IV every 21 days, with regular check-ups for 10 years after treatment.

• Participating requires frequent visits every 21 days.
• The study lasts up to 10 years with follow-ups.
• Potential side effects are monitored closely.